Innate Pharma : Deal with AstraZeneca is a game-changer – target price lifted to € 10.7 (vs € 5.80)
>New Deal with AstraZeneca – breathes new life into Innate - We are updating our model, following a company contact - post announcement of the new transformative deal with AstraZeneca. We are revising up our target price to € 10.7 (from € 5.8) thanks notably to 1/ the arrival of Lumoxiti in Innate Pharma's portfolio - a rare-cancer treatment that will be marketed in the US next year, 2/ promising clinical results for monalizumab in head-and-neck cancer - which trigger...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.